EP1381416B1 - Inhalationsgerät - Google Patents

Inhalationsgerät Download PDF

Info

Publication number
EP1381416B1
EP1381416B1 EP02725229A EP02725229A EP1381416B1 EP 1381416 B1 EP1381416 B1 EP 1381416B1 EP 02725229 A EP02725229 A EP 02725229A EP 02725229 A EP02725229 A EP 02725229A EP 1381416 B1 EP1381416 B1 EP 1381416B1
Authority
EP
European Patent Office
Prior art keywords
chamber
casing
powder
puncturing
ring
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP02725229A
Other languages
English (en)
French (fr)
Other versions
EP1381416A2 (de
Inventor
David Edwards
Mark Delong
Craig Dunbar
Ernest E. Penachio
Kevin Stapleton
Mark Wolff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Advanced Inhalation Research Inc
Original Assignee
Advanced Inhalation Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Inhalation Research Inc filed Critical Advanced Inhalation Research Inc
Publication of EP1381416A2 publication Critical patent/EP1381416A2/de
Application granted granted Critical
Publication of EP1381416B1 publication Critical patent/EP1381416B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/001—Particle size control
    • A61M11/003—Particle size control by passing the aerosol trough sieves or filters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0035—Piercing means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/003—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using capsules, e.g. to be perforated or broken-up
    • A61M15/0033—Details of the piercing or cutting means
    • A61M15/0041—Details of the piercing or cutting means with movable piercing or cutting means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Definitions

  • the present invention relates generally to facilitating release of powder contained in a receptacle. More specifically, the present invention relates to the administration of medication by an apparatus for facilitating inhalation of powder medicaments.
  • Each of these medications comes in a variety of forms, including fluids, which are commonly administered as an aerosol vapor or mist, as well as solids.
  • Inhalable solids typically take the form of fine, dry powders.
  • Specialized devices, such as inhalers, are provided to assist the patient in directing these fine powder medications into the respiratory tract.
  • U.S. Patent No. 5,787,881 discloses an inhaler that is used with encapsulated dry powder medicaments.
  • use of this device requires numerous steps and imposes a number of inconveniences on a user.
  • the medication capsules used with the device have an aperture formed therein prior to insertion into an opening in the inhaler. Therefore, there exists a danger that an amount of medication may be lost prior to or during insertion into the device. After insertion of the capsule, use of the device requires the additional step that a cover must be closed before the medication may be inhaled.
  • Inhalation devices configured for use with a capsule containing some type of medicament are shown in U.S. Patent No. 4,069,819 to Valentini et al. ("the '819 patent”) and U.S. Patent No. 4,995,385 to Valentini et al. (“the '385 patent”).
  • the inhalation device described in the '385 patent was developed to overcome the drawbacks of the device described in the '819 patent. Particularly, in a large number of cases, the device described in the '819 patent experienced irregular and incomplete emptying of the capsule, thereby resulting in difficulties in properly administering the medicament in the capsule.
  • the inhalation device described in the '385 patent attempts to overcome this deficiency by tapering the nebulization chamber toward the end surface that comprises the discharge holes.
  • the nebulization chamber of the '385 patent is not cylindrical, but rather frusto-conical in form in an attempt to achieve regular complete emptying of the nebulization chamber.
  • further improvements in the design of inhalation devices are needed to achieve a higher emitted dose.
  • "emitted dose” refers to the percentage of the dose of powder medicament, contained in a receptacle in the inhalation device, that is emitted from the inhalation device.
  • piercing device that is used to puncture the capsule.
  • Such conventional piercing devices are formed from circular stock, with the points created by pinching the stock at an angle, thereby creating a single sharp cutting edge.
  • Drawbacks of such a design are that the point (which must puncture the capsule material) is often rounded, lessening its effectiveness as a piercing device.
  • burrs often form on the lower edge, which can stop the piercing device from retracting from the capsule, thereby causing a device failure.
  • the holes formed by such a conventional piercing device are generally round, and do not have the appearance of being cut by a sharp edge.
  • the present invention relates to a device for emitting powder, comprising a casing comprising (i) a first casing portion, (ii) a cylindrical chamber, which is defined by a straight wall of circular cross-section, has a proximal end and a distal end, and comprises a ring circumferentially coupled to an inner surface thereof, and (iii) a second casing portion which is removably coupled to said first casing portion and comprises an emitter portion disposed at the proximal end of said chamber when said first and said second casing portions are coupled, said emitter portion defining at least one aperture configured to emit powder therethrough, characterised in that the cylindrical chamber is adapted to hold a powder receptacle and is coupled to the first casing portion and in that the ratio of the inner diameter of the ring to the inner diameter of the chamber is about 0.9 or less.
  • the device may be configured as an inhalation device for administering powder.
  • the emitter portion may be configured as an inhalation portion so that powder is dispersed in the chamber and administered to a user through the inhalation portion.
  • the inhalation portion may be configured as a mouth piece for inhalation through the mouth, or as a nose piece for inhalation through the nose.
  • the powder may be contained in a receptacle that is disposed in the chamber. Upon puncturing the receptacle, powder is dispersed in the chamber and emitted or inhaled from the device.
  • the device may include means for puncturing the receptacle.
  • the means for puncturing can be configured as a staple.
  • a staple is preferably configured in a substantially U-shape, having two prongs. Each of the prongs preferably has a square cross-section.
  • the substantially U-shaped staple may include a rounded portion and two prongs that define a non-planar inner edge and a non-planar outer edge of the staple, the staple being formed from a rectangular length having two end surfaces and four planar side surfaces that intersect to form four non-planar edges.
  • the inner edge of the staple is configured to be one of the non-planar edges, and the outer edge of the staple is the non-planar edge that is opposite that non-planar edge.
  • Each end surface is an angled diamond-shaped surface.
  • Each end surface may have a top point at an apex of the inner edge, and a bottom point at an apex of the outer edge, each top point forming a cutting point for one of the prongs.
  • One feature of the present invention is that it provides high emitted doses that are consistently reproducible over a range of flow rates and dosage quantity.
  • the present invention improves the emitted dose at both low flow rates and high dose ranges.
  • a particularly advantageous feature of the present invention is its ability to operate at low flow rates, such as would be associated with a child or a person with a respiratory disease.
  • One advantage of the device of the present invention is that the preferred means for puncturing used in the device is less expensive to manufacture than conventional piercing devices. Moreover, the means for puncturing advantageously provides improved puncturing performance since less force is needed to puncture the receptacles, and fewer failures result than with conventional piercing devices.
  • Another advantage of the preferred means for puncturing is an improvement to the flow rate independence of the inhaler. Consequently, the powdered medicament delivered to a patient will be independent of how fast the patient breathes, thereby ensuring that a consistent dose of medicament is delivered each time.
  • Another advantageous feature of the present invention is the accuracy of medicament dosage delivered thereby. Since only one dosage of medication is present in the inhaler during each use, the possibility of overdose is eliminated, and the medicament need not be metered prior to delivery. A patient may simply inhale all medicament present in the device.
  • the inhaler operates only under the inhalative power of the patient, the inhaler carries the additional advantage that no accessory device, such as a compressed air cylinder or other propellant, needs to be used in conjunction with the present invention.
  • Another advantage of the device of the present invention is that during inhalation, the medicament is subjected to mixing in the dispersion chamber. This helps to ensure that the medicament exiting the inhaler and entering the patient's respiratory system is in the form of a fine dry powder, facilitating medicament deposition in the lungs. In addition, inhalation of finer powders is typically more comfortable for the patient.
  • Still another advantage of the device of the present invention is that it can be used with individuals who cannot breathe hard, such as a child or an asthmatic, or individuals who are sleeping or in a coma.
  • Yet another advantage of the device of the present invention is that it is reusable. To reuse, a patient removes the emptied receptacle, and replaces it with a fresh receptacle filled with the proper dose of medicament.
  • the present invention provides an improved apparatus for facilitating release of powder.
  • the powder is contained in a receptacle.
  • the term ''receptacle'' includes but is not limited to, for example, a capsule, blister, film covered container well, chamber, and other suitable means of storing a powder known to those skilled in the art.
  • the present invention will be described below in the context of an apparatus for dispensing dry powder medicaments for inhalation by a patient.
  • an apparatus of the present invention is an inhaler that includes a chamber.
  • the chamber is configured to receive the receptacle containing the medicament.
  • the chamber includes a ring circumferentially coupled to an inner surface of the chamber.
  • the ring is preferably disposed at approximately a midpoint of the chamber, or alternatively, adjacent the proximal end of the chamber. In proper use, air will exit the inhaler carrying a full dose of medicament in the form of a fine, dry powder.
  • the inhaler of the present invention is preferably configured with a means for puncturing the receptacle that improves puncturing performance, particularly with brittle receptacle material.
  • the means for puncturing the receptacle of the present invention is preferably configured as a substantially U-shaped staple with two prongs, each prong having a sharp point and two cutting edges.
  • each prong has a square cross-section, with the staple material being bent around a face so that the innermost part of the U-shaped staple is flat.
  • the staple material is rotated 45 degrees so that it is bent around an edge so that the innermost part of the U-shaped staple is an edge.
  • the end surface of each prong is an angled diamond-shaped surface.
  • the inhaler is used to dispense powder by inhalation.
  • a user operates the device to puncture the receptacle to disperse powder in the chamber, and inhales the powder through the inhalation portion.
  • FIG. 1 A front view of an inhalation device 100 is shown in FIG. 1.
  • the rear view of device 100 is substantially identical to the front view.
  • Device 100 includes a first or lower casing portion 120 and a second or upper casing portion 130 removably coupled to first casing portion 120.
  • Upper casing portion 130 and lower casing portion 120 include a flattened region 132 and 122, respectively, for ease of gripping the casing for use by a patient.
  • Lower casing portion 120 preferably includes an outer casing 126 and an inner casing 124 movably received within outer casing 126.
  • a removable cap 110 is provided at the user or inhalation end of the device.
  • Preferred materials for device 100 include Food and Drug Administration (FDA) approved, USP tested plastics.
  • FDA Food and Drug Administration
  • device 100 is manufactured using an injection molding process, the details of which would be readily apparent to one skilled in the art.
  • FIG. 2 is a cross-section of device 100 shown in FIG. 1 along line 2-2.
  • device 100 includes an inhalation or emitter portion 220.
  • Inhalation portion 220 comprises a hemispheric region 222 that defines a plurality of apertures 224. It should be understood that the present invention is not limited to a particular number of apertures 224, and can be configured such that at least one aperture 224 is provided.
  • An inhalation piece 226 is provided to allow for inhalation of the medicament by a user.
  • Inhalation piece 226 can be configured as a mouth piece for inhalation through a user's mouth.
  • inhalation piece 226 can be configured as a nose piece for inhalation through a user's nose.
  • Device 100 includes a cylindrical chamber 210 that is defined by a straight wall 212 of circular cross-section.
  • Chamber 210 has a proximal end 214 and a distal end 216.
  • a plurality of slits 218 are defined by wall 212, and are configured for introducing air into chamber 210 to disperse powder released from a capsule 219. It should be understood that the present invention is not limited to a particular number of slits 218, and can be configured such that at least one slit 218 is provided. Powder released from capsule 219 is dispersed in chamber 210 and inhaled through apertures 224 and inhalation piece 226 by the user.
  • receptacles other than capsules are used, such as blisters and film covered container wells as are known in the art.
  • the volume of the receptacle is at least about 0.37 cm 3 .
  • the volume of the receptacle is at least about 0.48 cm 3 .
  • the receptacles have a volume of at least about 0.67 cm 3 or 0.95 cm 3 .
  • the receptacle is a capsule designated with a capsule size 2, 1, 0, 00, or 000. Suitable capsules can be obtained, for example, from Shionogi (Rockville, MD).
  • Blisters can be obtained, for example, from Hueck Foils, (Wall, NJ).
  • the receptacle encloses or stores particles, also referred to herein as powders.
  • the receptacle is filled with particles in a manner known to one skilled in the art. For example, vacuum filling or tamping technologies may be used. Generally, filling the receptacle with powder can be carried out by methods known in the art.
  • the particle or powder enclosed or stored in the receptacle have a mass of about 5 milligrams (mg). Preferably the mass of the particles stored or enclosed in the receptacle is at least about 10 mg.
  • particles used with the device have a tap density of less than about 0.4 g/ cm 3 .
  • Particles having a tap density of less than about 0.4 g/ cm 3 are referred to herein as "aerodynamically light".
  • the particles have a tap density of near to or less than about 0.1 g/cm 3 .
  • Tap density is a measure of the envelope mass density characterizing a particle.
  • the envelope mass density of particles of a statistically isotropic shape is defined as the mass of the particle divided by the minimum sphere envelope volume within which it can be enclosed.
  • Features that can contribute to low tap density include irregular surface texture and hollow or porous structure. Particularly preferred particles and powders are described in U.S. Patent Nos. 6,136,295, 5,985,309, 5,874,064, and 5,855,913, and U.S. Patent Appl. No. 09/591,307, filed June 9, 2000 entitled "High Efficient Delivery of a Large Therapeutic Mass Aerosol”.
  • Device 100 includes a means for puncturing 230 that is used to puncture capsule 219 to release powder contained therein into chamber 210.
  • means for puncturing 230 is configured as a substantially U-shaped staple having two prongs 232.
  • each of prongs 232 is configured with a square cross-section 234, thereby providing a sharp point and two cutting edges. This will be discussed in more detail below with respect to FIGS. 9A and 9B.
  • device 100 could alternatively be configured with the puncturing implement shown in FIGS. 7A through 7D.
  • the present invention is not limited to use of a substantially U-shaped staple as the means for puncturing the capsule. Alternatively, one, or a plurality of, straight needle-like implements could be used.
  • the puncturing implement is configured to puncture at least two holes in the capsule.
  • Means for puncturing 230 is preferably configured to be movable between a non-puncturing position (as depicted in FIG. 2 ) and a puncturing position. In the puncturing position, prongs 232 pierce or puncture capsule 219 to make holes therein.
  • a means for biasing is provided that biases the means for puncturing 230 in the non-puncturing position.
  • the means for biasing is configured as a spring 242 that biases the substantially U-shaped staple in the non-puncturing position.
  • device 100 includes inner casing 124 and outer casing 126.
  • a spring 244 is disposed in lower casing portion 120 that biases inner casing 124 in an outward position.
  • inner casing 124 moves from the outward position to an inward position, thereby drawing lower casing portion 120 toward upper casing portion 130.
  • Compression of spring 244 also causes compression of spring 242, thereby causing means for puncturing 230 to move to the puncturing position.
  • springs 242 and 244 return to their biased state, thereby returning means for puncturing 230 to its non-puncturing position, and inner casing 124 to its outward position.
  • a pair of flanges 252 is disposed on first casing portion 120.
  • a pair of grooves 254 is disposed on second casing portion 130 so that flanges 252 can be received within grooves 254 to thereby couple the first and second casing portions.
  • the first and second casing portions are coupled with a friction-fit engagement.
  • a friction-fit engagement can be achieved using the groove and flange arrangement depicted in FIG. 2.
  • Other alternative configurations for a friction-fit engagement would be readily apparent to one skilled in the art.
  • FIG. 3 is an enlarged partial cross-section of chamber 210 .
  • the chamber 210 does not contain a ring disposed on an inner surface, and an inner diameter of chamber 210 is depicted as "X". Such a configuration may be referred to herein as a "straight" chamber configuration.
  • FIG. 4 is an enlarged partial cross-section of an embodiment of chamber 210 in accordance with the invention as defined in claim 1.
  • a ring 400 is circumferentially coupled to an inner surface of chamber 210.
  • An inner diameter of ring 400 is depicted as "Y", and is less than inner diameter X of chamber 210.
  • ring 400 is disposed at approximately a midpoint of chamber 210. Such a configuration may be referred to herein as a "low” ring position or “low” chamber configuration.
  • ring 400 is disposed adjacent slits 218.
  • the ring position is measured by the distance from the top of hemispheric region 222 to the bottom edge of ring 400. This distance is depicted as "Z".
  • the following dimensions are provided as exemplary dimensions of a device of the present invention. It should be understood by one skilled in the art that the present invention is not limited to the dimensions provided herein.
  • diameter X is 1.19 cm (0.47 in.)
  • diameter Y is 0.97 cm (0.38 in.)
  • distance Z is 1.24 cm (0.49 in.).
  • FIG. 6 is an enlarged partial cross-section of another embodiment of chamber 210 in accordance with the invention.
  • ring 400 is circumferentially coupled to an inner surface of chamber 210.
  • An inner diameter of ring 400 is depicted as "Y", and is less than inner diameter X of chamber 210.
  • ring 400 is disposed adjacent the proximal end of chamber 210.
  • Such a configuration may be referred to herein as a "high” ring position or a "high” chamber configuration.
  • the ring position is measured by the distance from the top of hemispheric region 222 to the bottom edge of ring 400. This distance is depicted as "Z".
  • diameter X is 1.19 cm (0.47 in.)
  • diameter Y is 0.97 cm (0.38 in.)
  • distance Z is 0.74 cm (0.29 in.).
  • FIG. 5 is an enlarged partial cross-section of another embodiment of chamber 210 in accordance with the invention.
  • ring 400 is circumferentially coupled to an inner surface of chamber 210.
  • An inner diameter of ring 400 is depicted as "Y", and is less than inner diameter X of chamber 210.
  • ring 400 is disposed between the low ring position of FIG. 4 and the high ring position of FIG. 6.
  • Such a configuration may be referred to herein as a "mid” ring position or “mid” chamber configuration.
  • the ring position is measured by the distance from the top of hemispheric region 222 to the bottom edge of ring 400. This distance is depicted as "Z".
  • diameter X is 1.19 cm (0.47 in.)
  • diameter Y is 0.97 cm (0.38 in.)
  • distance Z is 0.99 cm (0.39 in.).
  • ring 400 is integral with chamber 210.
  • ring 400 and chamber 210 are formed as a unit, such as through an injection molding, extrusion or a casting process.
  • ring 400 is attached to the inner surface of chamber 210 in a manner known to those skilled in the art, such as through the use of glue or other type of adhesive, or by using an attaching device such as a pin or screw, etc.
  • the casing of device 100 is made from a material that can be injection molded, such as a plastic material (preferably FDA approved, USP tested).
  • the material is preferably durable, easy to clean, and non-reactive with powder medicaments.
  • Device 1500 includes a first or lower casing portion 1540 and a second or upper casing portion 1550 removably coupled to first casing portion 1540.
  • First and second casing portions 1540 and 1550 are coupled through the use of a flange 1552 and a groove 1554.
  • Preferred materials for device 1500 include Food and Drug Administration (FDA) approved, USP tested plastics.
  • FDA Food and Drug Administration
  • device 1500 is manufactured using an injection molding process, the details of which would be readily apparent to one skilled in the art.
  • Device 1500 includes an inhalation or emitter portion 1520.
  • Inhalation portion 1520 comprises a hemispheric region 1522 that defines a plurality of apertures 1524. It should be understood that the present invention is not limited to a particular number of apertures 1524, and can be configured such that at least one aperture 1524 is provided.
  • An inhalation piece 1526 is provided to allow for inhalation of the medicament by a user. Inhalation piece 1526 can be configured as a mouth piece for inhalation through a user's mouth. Alternatively, inhalation piece 1526 can be configured as a nose piece for inhalation through a user's nose.
  • Device 1500 includes a cylindrical chamber 1510 that is defined by a straight wall 1512 of circular cross-section.
  • a plurality of slits 1518 are defined by wall 1512, and are configured for introducing air into chamber 1510 to disperse powder released from, for example, capsule 219 as illustrated in FIG. 2. It should be understood that the present invention is not limited to a particular number of slits 1518, and can be configured such that at least one slit 1518 is provided. Powder released from capsule 219 is dispersed in chamber 1510 and inhaled through apertures 1524 and inhalation piece 1526 by the user.
  • device 1500 can be configured with means for puncturing and means for biasing in a manner similar to that described above with respect to the device shown in FIGS. 1 and 2. Means for puncturing are described in more detail below with respect to FIGS. 7A through 7D, 8, 9A, and 9B. Moreover, device 1500 can be configured with the chamber designs described above with respect to FIGS. 3-6.
  • the flow rates were measured with a flow meter.
  • the emitted dose measurement involved placing a capsule into four embodiments of the inhaler of the present invention for actuation into an emitted dose (ED) measurement apparatus.
  • the ED apparatus included a powder filter and a filter holder.
  • the powder collected by the ED apparatus was quantified by fluorescence spectrophotometry.
  • the straight configuration is shown in FIG. 3; the low configuration is shown in FIG. 4; the mid configuration is shown in FIG.
  • each of the low, mid, and high configurations demonstrated a higher emitted dose at each of the three flow rates than the straight (no ring) configuration.
  • the ring configuration of the present invention provides an improvement over conventional chamber designs without a ring, such as those shown in the '819 and '385 patents.
  • the low configuration produced a higher emitted dose and a lower standard deviation than the mid and high configurations.
  • FIG. 11 is a bar graph illustrating emitted dose at low flow rates for devices with varying numbers of slits 218.
  • a flow rate of less than about 15 L/min will be referred to herein as a "low flow rate.”
  • the measurements were taken at a flow rate of 5 L/min, with a volume of 67 cc and a 15 mg dosage.
  • the emitted dose increases so that the device of the present invention successfully delivers a high emitted dose at low flow rate over multiple (ten) actuations.
  • the device of the present invention achieves a high emitted dose at low flow rates that is consistently reproducible with low standard deviation.
  • the ratio of the inner diameter of the ring to the inner diameter of the chamber is about 0.8.
  • inner diameter X of chamber 210 is 0.84 cm (0.33 in.) and inner diameter Y of ring 400 is 0.76 cm (0.30 in.).
  • the ratio of the inner diameter of the ring to the inner diameter of the chamber is about 0.9.
  • the ratio of the inner diameter of the ring to the inner diameter of the chamber is about 0.9 or less.
  • the device of the present invention can also be optimized for varying dosage ranges.
  • One way to do so is to vary the dimensions of chamber 210 to accommodate varying sizes of capsules.
  • a chamber having an inner diameter X of 0.84 cm (0.33 in.), inner diameter Y of 0.76 cm (0.30 in.), and distance Z of 1.45 cm (0.57 in.) can be used with size 2 and size 00 capsules.
  • chamber 210 can be scaled to accommodate varying capsule sizes, and to accommodate those capsule sizes at varying flow rates.
  • the device of the present invention can be used with varying dosage ranges.
  • a highly dispersible powder was prepared and loaded into capsules to obtain a large pre-metered dose (50 mg) and a smaller pre-metered dose (6 mg).
  • the aerodynamic particle size distributions were characterized using a multistage liquid impinger that extracted air at 60 L/min after actuating the inhaler device (D). As shown in FIG.
  • FIG. 12 shows the results comparing the two particle size distributions obtained for the 6 mg (left bar) and 50 mg (right bar) doses.
  • "ED" used on the graph refers to emitted dose
  • FPM used on the graph refers to fine particle mass (estimate of the mass that would deposit in the lungs).
  • the fine particle fraction ⁇ 6.8 ⁇ m relative to the total dose (FPF TD ⁇ 6.8 ⁇ m) for the 6 and 50 mg doses were 74.4% and 75.0%, respectively. Similar aerodynamic particle size distributions were obtained for both doses.
  • FIG. 13 is a graph showing glucose (mg/dL) in beagle dogs after administration of human insulin using an aerosol generator and a device of the present invention with the low ring configuration substantially as shown in FIG. 4.
  • the generator is a device with proven ability for forming a respirable aerosol that results in deposition of powder in dog lungs. Metered powder is presented to a chamber where the powder is dispersed by a high velocity jet of air. The dispersed powder is directed toward a baffle to separate large agglomerates before inhalation by the dog.
  • the pharmakodynamic profile shown in FIG.13 confirms that the device of the present invention produces a pattern of powder deposition similar to the aerosol generator.
  • the dogs were anesthetized for the dosing procedure.
  • a forced maneuver was used with dogs being ventilated at 75% of their vital capacity (approximately 100 cc/s or 6 L/min for a duration of 1 second).
  • a 4 second breath-hold was applied at the end of each inhalation.
  • a physically smaller device was used with the low ring configuration to facilitate administration. The device performed well at the low flow rate with the anesthetized dogs using the forced maneuver. Based on these results, such a device could be used with a sleeping person or a person having breathing problems, such as from chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the device of the present invention relies upon the breath of the user to drive the inhalation process, yet the device is configured to work successfully at low flow rates.
  • the device of the present invention has particular suitability for use with individuals who cannot breath hard, such as a child, an individual with respiratory disease, or individuals who are sleeping or in a coma.
  • the staple preferably comprises a rectangular length of material that has four planar side surfaces 730. Each planar side surface intersects with two other planar side surfaces to create a total of four non-planar edges 736.
  • the staple is preferably bent into a substantially U-shaped configuration, thereby having a rounded portion and two prongs 732.
  • the prongs 732 terminate at two end surfaces 731. As best seen in FIGS. 7A, 7C and 7D, end surfaces 731 are diamond-shaped.
  • each prong 732 has an inner surface 738 that comprises one of the non-planar edges and an outer surface 740 that comprises the opposite non-planar edge.
  • the inner surface 738 of each prong 732 terminates at the uppermost portion 737 of the diamond-shaped end surface, thereby creating a cutting edge for the prong.
  • the outer surface 740 of the prong 732 terminates at the lowermost portion 735 of the diamond-shaped end surface.
  • FIGS. 9A and 9B depict another embodiment of a staple suitable for use in the present invention.
  • This staple preferably comprises a rectangular length of material that has four planar side surfaces. Each planar side surface intersects with two other planar side surfaces to create a total of four non-planar edges.
  • the staple is preferably bent into a substantially U-shaped configuration, thereby having a rounded portion and two prongs. The prongs terminate at two end surfaces that have a square shape.
  • each prong has an inner surface that comprises one of the planar side surfaces and an outer surface that comprises the opposite planar side surface.
  • the inner surface of each prong terminates at the uppermost portion of the square-shaped end surface, thereby creating a cutting edge for the prong.
  • the outer surface of the prong terminates at the lowermost portion of the square-shaped end surface.
  • FIG. 9B illustrates a puncture obtained from using the staple depicted in FIG. 9A.
  • the holes formed by this staple have the appearance of being cut with a sharp edge.
  • the material removed to create the hole is peeled back and remains well attached to the capsule; thereby preventing the capsule material from being inhaled by the user when the powder medicament is being dispensed.
  • FIG. 8 illustrates a puncture obtained from using the staple depicted in FIGS. 7A-7D.
  • the holes formed by the staple appear to be cut with a sharp edge, and the excess material is peeled back.
  • the effort required to puncture the capsule is lower than circular section staples, and approximately the same as a square section staple.
  • These staples are extremely inexpensive to produce, approximately one-third the cost of square section staples such as those depicted in FIG 9A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Manipulator (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (27)

  1. Gerät (100; 1500) zur Abgabe von Pulver, welches Gerät aufweist:
    ein Gehäuse, welches (i) einen ersten Gehäuseabschnitt (120; 1540), (ii) eine zylindrische Kammer (210; 1510), die durch eine gerade Wand (212; 1512) mit kreisförmigem Querschnitt begrenzt ist, welche Kammer ein proximales Ende (214) und ein distales Ende (216), und einen Ring (400) aufweist, welcher ringsum mit einer Innenfläche davon vorgesehen ist, und (iii) einen zweiten Gehäuseabschnitt (130; 1550) aufweist, welcher lösbar mit dem ersten Gehäuseabschnitt (120; 1540) verbunden ist und einen Ausgabeabschnitt (220; 1520) aufweist, welcher sich am proximalen Ende der Kammer (210; 1510) befindet, wenn der erste (120; 1540) und zweite (130; 1550) Gehäuseabschnitt miteinander gekoppelt sind, wobei der Ausgabeabschnitt (220; 1520) zumindest eine Öffnung (224; 1524) begrenzt, welche ausgebildet ist, das Pulver durch sie hindurch abzugeben;
    dadurch gekennzeichnet, dass die zylindrische Kammer (210; 1510) so ausgebildet ist, dass sie einen Pulverbehälter (219) hält, und mit dem ersten Gehäuseabschnitt (120; 1540) verbunden ist, wobei das Verhältnis des Innendurchmessers des Rings (400) zum Innendurchmesser der Kammer (210; 1510) etwa 0,9 oder weniger beträgt.
  2. Gerät (100; 1500) nach Anspruch 1, wobei sich der Ring (400) etwa an einem Mittelpunkt der Kammer (210; 1510) befindet.
  3. Gerät (100; 1500) nach Anspruch 1, wobei sich der Ring (400) neben dem proximalen Ende (214) der Kammer (210; 1510) befindet.
  4. Gerät (100; 1500) nach Anspruch 1, 2 oder 3, wobei der Ring (400) in die Kammer (210; 1510) integriert ist.
  5. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches im Gehäuse ferner Mittel (230) zum Durchstechen des Behälters (219), welcher das Pulver enthält, aufweist.
  6. Gerät (100; 1500) nach Anspruch 5, wobei das Mittel zum Durchstechen (230) zwischen einer nicht-durchstechenden Position und einer durchstechenden Position bewegbar ist.
  7. Gerät (100; 1500) nach Anspruch 6, welches ferner Mittel zum Vorspannen (244) des Mittels zum Durchstechen (230) in der nicht-durchstechenden Position umfasst.
  8. Gerät (100; 1500) nach Anspruch 5, 6 oder 7, wobei das Mittel zum Durchstechen (230) so gestaltet ist, dass es mindestens zwei Löcher in den Behälter (219) sticht.
  9. Gerät (100; 1500) nach Anspruch 8, wobei das Mittel zum Durchstechen (230) eine im Wesentlichen U-förmige Krampe umfasst, welche zwei Zinken (232; 732) aufweist.
  10. Gerät (100; 1500) nach Anspruch 9, wobei jede der Zinken (232; 732) einen quadratischen Querschnitt aufweist.
  11. Gerät (100; 1500) nach Anspruch 9 oder 10, wobei die im Wesentlichen U-förmige Krampe einen gerundeten Abschnitt und zwei Zinken (732) aufweist, welche eine nichtebene Innenkante (738) und eine nichtebene Außenkante (740) der Krampe bilden, wobei die Krampe aus einem rechteckigen langgestreckten Körper mit zwei Endflächen (731) und vier ebenen Seitenflächen gebildet ist, welche sich kreuzen, um vier nichtebene Kanten zu bilden, wobei die Innenkante (738) der Krampe eine der nichtebenen Kanten ist und die Außenkante (740) ist eine andere der nichtebenen Kanten, welche sich gegenüber der einen nichtebenen Kante befindet, wobei jede Endfläche (731) eine winklige, rautenförmige Fläche aufweist.
  12. Gerät (100; 1500) nach Anspruch 11, wobei jede Endfläche einen oberen Punkt (737) an einem Scheitel der Innenkante und einen unteren Punkt an einem Scheitel der Außenkante aufweist, wobei jeder obere Punkt (737) einen Schnittpunkt für eine der Zinken bildet.
  13. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches ferner ein Mundstück (226; 1526) aufweist, durch welches ein Benutzer das Pulver in seinen Mund inhaliert.
  14. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches ferner ein Nasenstück aufweist, durch welches ein Benutzer das Pulver in seine Nase inhaliert.
  15. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, wobei der Abgabeabschnitt (220; 1520) eine halbkugelförmige Region (222; 1522) aufweist, welche mehrere Öffnungen (224; 1524) umgrenzt, welche so ausgebildet sind, dass das Pulver durch sie hindurch abgegeben wird.
  16. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches so aufgebaut ist, dass es Pulver durch die mindestens eine Öffnung (224) abgibt, und zwar als Reaktion auf die Inhalation durch einen Benutzer mit einem Durchfluss von weniger als etwa 15 1/min.
  17. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches ferner mehrere durch die Wand (212; 1512) umgrenzte Schlitze (218; 1518) aufweist, wobei die mehreren Schlitze (218; 1518) so ausgebildet sind, dass sie Luft in die Kammer (210; 1510) einströmen lassen.
  18. Gerät (100; 1500) nach Anspruch 17, wobei sich der Ring (400) neben den mehreren Schlitzen (218) angeordnet ist.
  19. Gerät (100; 1500) nach einem der Ansprüche 5 bis 18, wobei sich das Mittel zum Durchstechen (230) im ersten Gehäuseabschnitt (120) befindet.
  20. Gerät (100; 1500) nach einem der Ansprüche 7 bis 19, wobei das Mittel zum Vorspannen eine Feder (244) ist, welche sich im ersten Gehäuseabschnitt (120) befindet.
  21. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, wobei der erste Gehäuseabschnitt (120) Folgendes aufweist:
    ein Außengehäuse (126); und
    ein Innengehäuse (124), das beweglich in dem Außengehäuse (126) aufgenommen ist.
  22. Gerät (100; 1500) nach Anspruch 21, wenn an Anspruch 20 angeschlossen, wobei die Feder (244) das Innengehäuse (124) in einer außen liegende Position vorspannt, und beim Zusammendrücken der Feder (244) sich das Innengehäuse (124) von der außen liegenden Position in eine innen liegende Position bewegt.
  23. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches ferner Folgendes umfasst:
    ein Flanschpaar (252), welche dem ersten Gehäuseabschnitt (120) angeordnet ist; und
    ein Rillenpaar (254), welche auf dem zweiten Gehäuseabschnitt (130) angeordnet ist, um das Flanschpaar (252) darin aufzunehmen, wodurch der erste (120) und zweite (130) Gehäuseabschnitt verbunden sind.
  24. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, wobei der erste (120) und zweite (130) Gehäuseabschnitt durch reibschlüssiges Eingreifen verbunden sind.
  25. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches ferner eine lösbare Kappe (110) für den Abgabeabschnitt (220) umfasst.
  26. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, wobei das Verhältnis etwa 0,8 ist.
  27. Gerät (100; 1500) nach einem der vorhergehenden Ansprüche, welches ferner einen Behälter (219) umfasst, welcher das in der Kammer (210) befindliche Pulver enthält, wobei beim Durchstechen des Behälters (219) Pulver in die Kammer (210) abgegeben und einem Benutzer durch die mindestens eine Öffnung (224) verabreicht wird.
EP02725229A 2001-04-16 2002-03-20 Inhalationsgerät Expired - Lifetime EP1381416B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/835,302 US6766799B2 (en) 2001-04-16 2001-04-16 Inhalation device
US835302 2001-04-16
PCT/US2002/008298 WO2002083220A2 (en) 2001-04-16 2002-03-20 Inhalation device and method

Publications (2)

Publication Number Publication Date
EP1381416A2 EP1381416A2 (de) 2004-01-21
EP1381416B1 true EP1381416B1 (de) 2006-01-25

Family

ID=25269161

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02725229A Expired - Lifetime EP1381416B1 (de) 2001-04-16 2002-03-20 Inhalationsgerät

Country Status (16)

Country Link
US (6) US6766799B2 (de)
EP (1) EP1381416B1 (de)
JP (1) JP2004526523A (de)
AT (1) ATE316397T1 (de)
AU (1) AU2002255808B2 (de)
CA (1) CA2444129C (de)
CY (1) CY1108214T1 (de)
DE (1) DE60208891T2 (de)
DK (1) DK1381416T3 (de)
ES (1) ES2256467T3 (de)
HK (1) HK1061658A1 (de)
IL (2) IL158357A0 (de)
MX (1) MXPA03009412A (de)
NZ (1) NZ528682A (de)
PL (1) PL204303B1 (de)
WO (1) WO2002083220A2 (de)

Families Citing this family (146)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69918267T2 (de) 1998-01-16 2005-07-28 1263152 Ontario Inc., London Anzeigevorrichtung zur verwendung mit einer abgabevorrichtung
US6082358A (en) 1998-05-05 2000-07-04 1263152 Ontario Inc. Indicating device for aerosol container
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
WO2002013897A2 (en) * 2000-08-14 2002-02-21 Advanced Inhalation Research, Inc. Inhalation device and method
GB0023654D0 (en) * 2000-09-27 2000-11-08 Cambridge Consultants Device for administering doses of particulate material
US6766799B2 (en) * 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
ITMI20010357U1 (it) * 2001-06-28 2002-12-30 Plastiape Spa Dispositivo inalatore
EP1443996B1 (de) * 2001-11-14 2011-05-18 Novartis AG Aerosol-vernebler bestehend aus koppelbarem haupt- und endstück
EP1894591B1 (de) 2002-03-20 2013-06-26 MannKind Corporation Kartusche für eine Inhalationsvorrichtung
EP1487411B1 (de) 2002-03-20 2019-01-02 Civitas Therapeutics, Inc. Inhalierbare therapeutische depot-formulierungen
ATE394136T1 (de) * 2002-03-20 2008-05-15 Alkermes Inc Inhalationsgerät für pulverförmige substanzen
US7004164B2 (en) * 2002-03-21 2006-02-28 Trudell Medical International Indicating device for aerosol container
ES2638987T3 (es) 2002-06-28 2017-10-25 Civitas Therapeutics, Inc. Epinefrina inhalable
BR0306930A (pt) * 2002-10-11 2004-11-09 Otsuka Pharma Co Ltd Inalador de pó
DE10258360A1 (de) 2002-12-12 2004-06-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pulverinhalator mit Kapselkammer zum Aufnehmen einer mit Wirkstoff gefüllten Einwegkapsel
US7284553B2 (en) 2002-12-12 2007-10-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder inhaler comprising a chamber for a capsule for taking up a non-returnable capsule being filled with an active ingredient
US20040206350A1 (en) * 2002-12-19 2004-10-21 Nektar Therapeutics Aerosolization apparatus with non-circular aerosolization chamber
PL1615689T3 (pl) 2003-04-09 2016-06-30 Novartis Ag Urządzenie do aerozolizacji z prowadnicą wyrównującą do przebijania kapsułki
PL1610850T3 (pl) 2003-04-09 2012-11-30 Novartis Ag Urządzenie rozpylające z osłoną wlotu powietrza
US8869794B1 (en) 2003-04-09 2014-10-28 Novartis Pharma Ag Aerosolization apparatus with capsule puncturing member
WO2004112702A2 (en) 2003-06-13 2004-12-29 Advanced Inhalation Research, Inc. Low dose pharmaceutical powders for inhalation
US7621273B2 (en) 2003-10-28 2009-11-24 Trudell Medical International Indicating device with warning dosage indicator
US7100530B2 (en) 2003-12-15 2006-09-05 Trudell Medical International, Inc. Dose indicating device
AU2005209199B2 (en) * 2004-01-16 2008-09-11 Biodel Inc. Sublingual drug delivery device
CA2563365A1 (en) * 2004-04-23 2005-11-03 Mystic Pharmaceuticals, Inc. Multiple unit dose drug delivery system
SE528190C2 (sv) * 2004-06-07 2006-09-19 Mederio Ag Inhalator
JP2008503586A (ja) 2004-06-21 2008-02-07 ネクター セラピューティクス アンフォテリシンｂを含む組成物、方法、およびシステム
US8513204B2 (en) 2004-06-21 2013-08-20 Novartis Ag Compositions comprising amphotericin B, mehods and systems
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
CN104436170B (zh) 2004-08-23 2018-02-23 曼金德公司 用于药物输送的二酮哌嗪盐
US7543582B2 (en) 2004-09-20 2009-06-09 Trudell Medical International Dose indicating device with display elements attached to container
BRPI0517374A (pt) 2004-10-29 2008-10-07 Harvard College formulação para tratamento ou prevenção de infecção respiratória, método para tratamento
US20060105051A1 (en) * 2004-11-18 2006-05-18 Blair Jackson Manufacture of particles for pulmonary drug delivery by carbon dioxide assisted nebulization
US20060129460A1 (en) * 2004-12-09 2006-06-15 Innerfund, Ltd. Internet service provider branded facades
US20060134009A1 (en) * 2004-12-16 2006-06-22 Daniel Deaver Low dose corticosteroid powders for inhalation
US7886934B2 (en) 2005-01-20 2011-02-15 Trudell Medical International Dispensing device
GB0507711D0 (en) 2005-04-15 2005-05-25 Vectura Group Plc Improved blister piercing
HUE028623T2 (en) 2005-09-14 2016-12-28 Mannkind Corp Active substance formulation method based on increasing the affinity of the active ingredient for binding to the surface of crystalline microparticles
US20070123449A1 (en) * 2005-11-01 2007-05-31 Advanced Inhalation Research, Inc. High load particles for inhalation having rapid release properties
IN2015DN00888A (de) 2006-02-22 2015-07-10 Mannkind Corp
DE102006010089A1 (de) * 2006-02-24 2007-10-18 Aha-Kunststofftechnik Gmbh Trockenpulver-Inhalator
US8360057B2 (en) * 2006-03-10 2013-01-29 Dose One, Llc Medication inhaler for dispensing multiple capsules
US7832399B2 (en) * 2006-03-10 2010-11-16 One Dose, Llc Medication inhaler
US8464712B2 (en) * 2006-03-10 2013-06-18 Dose One, Llc Medication inhaler
US8141550B2 (en) 2006-08-01 2012-03-27 Trudell Medical International Dispensing device
US20080063722A1 (en) * 2006-09-08 2008-03-13 Advanced Inhalation Research, Inc. Composition of a Spray-Dried Powder for Pulmonary Delivery of a Long Acting Neuraminidase Inhibitor (LANI)
NL1033047C2 (nl) * 2006-12-13 2008-06-16 Pharmachemie Bv Capsule, gevuld met een medicijn, in het bijzonder een inhaleerbaar medicijn.
EP2109475B1 (de) 2007-01-09 2019-11-27 Mystic Pharmaceuticals, Inc. Intranasale kartuschenvorrichtungen
US20080210228A1 (en) * 2007-03-02 2008-09-04 Corbco, Inc. Monodose nasal sprayer
US20080233199A1 (en) * 2007-03-22 2008-09-25 Alkermes, Inc. Coacervation Process
WO2008144439A1 (en) * 2007-05-16 2008-11-27 Mystic Pharmaceuticals, Inc. Combination unit dose dispensing containers
US9248076B2 (en) 2007-05-16 2016-02-02 Mystic Pharmaceuticals, Inc. Dose dispensing containers
US8683995B2 (en) 2007-05-16 2014-04-01 Mystic Pharmaceuticals, Inc. Dose dispensing containers
WO2008156586A2 (en) * 2007-06-12 2008-12-24 Alkermes, Inc. Inhalation device for powdered substances
CA2699634C (en) * 2007-09-14 2015-06-09 Mystic Pharmaceuticals, Inc. Deep draw container forming method
EP2534958A1 (de) 2007-12-14 2012-12-19 AeroDesigns, Inc Abgabe von Aerosol-sprühbaren Nahrungsmittelprodukten
WO2009091780A2 (en) * 2008-01-14 2009-07-23 Dr. Reddy's Laboratories Ltd. Device for inhaling powdered medicaments
US8082873B2 (en) 2008-05-05 2011-12-27 Trudell Medical International Drive mechanism for an indicating device
AU2009246217B2 (en) 2008-05-15 2013-01-10 Novartis Ag Pulmonary delivery of a fluoroquinolone
US8181591B1 (en) 2008-05-23 2012-05-22 Trudell Medical International Domed actuator for indicating device
ES2570400T3 (es) 2008-06-13 2016-05-18 Mannkind Corp Un inhalador de polvo seco y un sistema para el suministro de fármacos
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
CA2683353C (en) 2008-10-22 2015-12-15 Trudell Medical International Modular aerosol delivery system
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
EP2405963B1 (de) 2009-03-11 2013-11-06 MannKind Corporation Gerät, system und verfahren zur messung von widerstand in einem inhaliergerät
JP2012520890A (ja) 2009-03-18 2012-09-10 インカーダ セラピューティクス， インコーポレイテッド 経肺投与によって心疾患を治療するための単位用量、エアロゾル、キット、および方法
MX354829B (es) 2009-03-26 2018-03-22 Pulmatrix Operating Co Inc Formulaciones de polvo seco y metodos para el tratamiento de enfermedades pulmonares.
KR101875969B1 (ko) 2009-06-12 2018-07-06 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
RU2549310C2 (ru) 2009-09-21 2015-04-27 Ново Нордиск А/С Система для доставки лекарственных средств
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
AU2010319328A1 (en) 2009-11-12 2012-05-31 Stc.Unm Dry powder inhaler with flutter dispersion member
PT105065B (pt) * 2010-04-26 2012-07-31 Hovione Farmaciencia S A Um inalador simples de cápsulas
MX359281B (es) 2010-06-21 2018-09-21 Mannkind Corp Sistema y metodos para suministrar un farmaco en polvo seco.
AU2011296343B2 (en) 2010-08-30 2015-12-10 Pulmatrix Operating Company, Inc. Dry powder formulations and methods for treating pulmonary diseases
EP2464346A1 (de) 2010-08-30 2012-06-20 Pulmatrix, Inc. Behandlung zystischer fibrose mit calciumlactat, leukin und natriumchlorid in einem einatembaren trockenpulver
CN107096014B (zh) 2010-09-29 2022-07-15 普马特里克斯营业公司 吸入用单价金属阳离子干粉剂
DK2621488T3 (en) 2010-09-29 2019-03-04 Pulmatrix Operating Co Inc CATIONIC DRY POWDER
TR201109804A2 (tr) * 2010-10-07 2012-05-21 Bi̇lgi̇ç Mahmut Tek dozlu inhalasyon cihazı.
WO2012078804A1 (en) 2010-12-07 2012-06-14 Respira Therapeutics, Inc. Dry powder inhaler
MX353285B (es) 2011-04-01 2018-01-05 Mannkind Corp Paquete de blister para cartuchos farmaceuticos.
RO127873A2 (ro) * 2011-04-04 2012-10-30 Salt Pharma S.R.L. Dispozitiv de inhalare bifuncţional
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
CN103945859A (zh) 2011-10-24 2014-07-23 曼金德公司 用于治疗疼痛的方法和组合物
US10463815B2 (en) 2012-02-21 2019-11-05 Respira Therapeutics, Inc. Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
WO2014012069A2 (en) 2012-07-12 2014-01-16 Mannkind Corporation Dry powder drug delivery systems and methods
EP2911690A1 (de) 2012-10-26 2015-09-02 MannKind Corporation Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
BR112015010601B1 (pt) 2012-11-09 2022-07-19 Civitas Therapeutics, Inc. Composição farmacêutica e uso da composição
US20140150787A1 (en) * 2012-12-04 2014-06-05 Civitas Therapeutics, Inc. Devices and methods for puncturing a capsule to release a powdered medicament therefrom
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
GB201301192D0 (en) 2013-01-23 2013-03-06 Vectura Delivery Devices Ltd A blister piercing element for a dry powder inhaler
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
BR112015015560A2 (pt) * 2013-03-28 2017-07-11 Halliburton Energy Services Inc método de calibração para ferramentas de indução de múltiplos componentes
CN105324106A (zh) 2013-04-01 2016-02-10 普马特里克斯营业公司 噻托铵干粉
EP3607941A1 (de) 2013-04-30 2020-02-12 Otitopic Inc. Trockenpulverformulierungen und verfahren zur verwendung
KR102321339B1 (ko) 2013-07-18 2021-11-02 맨카인드 코포레이션 열-안정성 건조 분말 약제학적 조성물 및 방법
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
EP3046608B1 (de) 2013-09-21 2019-03-20 Inspirx, Inc. Atmungsbetätigter vernebler
WO2015097662A1 (en) * 2013-12-23 2015-07-02 Glenmark Pharmaceuticals Ltd A dry powder inhaler
US10238820B2 (en) * 2014-01-08 2019-03-26 Seroton, Inc. Dry-powder inhalation device
US11491288B2 (en) 2014-01-08 2022-11-08 Seroton, Inc. Dispenser for dry-powder inhalation devices
ES2922206T3 (es) 2014-02-20 2022-09-09 Otitopic Inc Formulaciones de polvo seco para la inhalación
USD752734S1 (en) 2014-03-10 2016-03-29 Civitas Therapeutics, Inc. Inhaler grip
USD755367S1 (en) 2014-03-10 2016-05-03 Civitas Therapeutics, Inc. Indicator for an inhaler
USD752204S1 (en) 2014-03-10 2016-03-22 Civitas Therapeutics, Inc. Indicator for an inhaler
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
MA40910A (fr) 2014-11-07 2017-09-12 Civitas Therapeutics Inc Poudres de rapamycine pour administration pulmonaire
MX2017009112A (es) 2015-01-14 2018-06-15 Respira Therapeutics Inc Metodos y dispositivos de dispersion de polvo.
JP2018514564A (ja) 2015-05-01 2018-06-07 サイヴィタス セラピューティックス，インコーポレイテッド 肺送達用のゾルミトリプタン粉末
EP3316865A4 (de) 2015-07-02 2019-01-23 Civitas Therapeutics, Inc. Triptanpulver zur pulmonalen verabreichung
CN104984451A (zh) * 2015-07-30 2015-10-21 中山市美捷时包装制品有限公司 一种笔形胶囊干粉吸入器
IL260335B2 (en) 2016-02-01 2023-10-01 Incarda Therapeutics Inc Combining electronic monitoring with inhaled pharmacological therapy for the management of cardiac arrhythmia including atrial fibrillation
WO2018002044A1 (en) 2016-06-29 2018-01-04 Novo Nordisk A/S Drug delivery device with drug differentiation feature
PL3481471T3 (pl) * 2016-07-07 2021-01-11 Philip Morris Products S.A. Układ inhalatora nikotyny
US11014941B2 (en) 2017-04-24 2021-05-25 Cocrystal Pharma, Inc. Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
AU2018266199A1 (en) 2017-05-10 2019-11-07 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
EP3634160B1 (de) * 2017-06-06 2021-07-28 JT International SA Inhalatorvorrichtung und verbrauchskartusche
WO2019084293A1 (en) 2017-10-25 2019-05-02 Arizona Board Of Regents On Behalf Of The University Of Arizona COMPOSITIONS AND METHODS FOR ADMINISTERING PHARMACEUTICAL AGENTS
US11667612B2 (en) 2017-10-25 2023-06-06 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
WO2019082056A1 (en) * 2017-10-25 2019-05-02 Philip Morris Products S.A. INHALER WITH DELIMITATION ELEMENT
WO2019143981A1 (en) 2018-01-19 2019-07-25 Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for delivering pharmaceutical agents
EP3768378A4 (de) 2018-03-22 2021-11-17 InCarda Therapeutics, Inc. Neuartiges verfahren zur verlangsamung der ventrikulären rate
MX2021000917A (es) 2018-07-27 2021-06-23 Cocrystal Pharma Inc Derivados de pirrolo[2,3-b]piridina como inhibidores de la replicación del virus de la gripe.
CN113286793B (zh) 2018-09-10 2024-04-05 共结晶制药公司 吡咯并吡嗪和吡啶并三嗪类流感病毒复制抑制剂
MX2021004215A (es) 2018-10-17 2021-07-15 Cocrystal Pharma Inc Combinaciones de inhibidores de la replicación del virus de la gripe.
EP3887355A1 (de) 2018-11-26 2021-10-06 Cocrystal Pharma, Inc. Inhibitoren der influenzavirenreplikation
MX2021010484A (es) * 2019-03-05 2021-10-01 Philip Morris Products Sa Soporte para articulo inhalador.
BR112021021775A2 (pt) 2019-04-29 2022-01-04 Insmed Inc Composições de pó seco de pró-fármacos de treprostinil e métodos de uso destas
WO2020239696A1 (en) 2019-05-24 2020-12-03 Stichting Katholieke Universiteit Improved administration of glycylcyclines by inhalation
US10828432B1 (en) * 2019-06-24 2020-11-10 De Motu Cordis Pty Ltd Respiratory delivery device and method
US11793951B2 (en) 2019-06-24 2023-10-24 De Motu Cordis Pty Ltd Automatic dispenser for respiratory delivery device and method
US11717621B2 (en) 2019-06-24 2023-08-08 De Motu Cordis Pty Ltd Automatic dispenser for respiratory delivery device
US11007185B2 (en) 2019-08-01 2021-05-18 Incarda Therapeutics, Inc. Antiarrhythmic formulation
WO2021188620A1 (en) 2020-03-17 2021-09-23 Cocrystal Pharma Inc. Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
KR20230008079A (ko) 2020-04-10 2023-01-13 코크리스탈 파마, 아이엔씨. 노로바이러스 및 코로나바이러스 복제 억제제
TW202228792A (zh) 2020-10-09 2022-08-01 殷漢生技股份有限公司 吸入用奈米載體製劑
FR3116440A1 (fr) * 2020-11-20 2022-05-27 Nemera La Verpilliere Embout pour dispositif de distribution de produit
WO2022189662A1 (en) 2021-03-12 2022-09-15 Alvarius Pharmaceuticals Ltd. Compositions and methods for treating addictions comprising 5-meo-dmt
CA3227602A1 (en) 2021-08-03 2023-02-09 Irina C. Jacobson Inhibitors for coronaviruses
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
USD1039680S1 (en) * 2023-01-09 2024-08-20 Ripple+ Limited Aromatherapy inhalation device
US11937633B1 (en) 2023-05-25 2024-03-26 Next Level Ventures LLC Vaping mouthpiece locking structure

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669113A (en) * 1966-03-07 1972-06-13 Fisons Ltd Inhalation device
US3888253A (en) * 1972-08-04 1975-06-10 Beecham Group Ltd Device for administration of medicines
EP0388621A1 (de) * 1989-02-23 1990-09-26 PHIDEA S.p.A. Zur vollständigen Entleerung der Kapsel geeigneter Inhalator

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3425414A (en) * 1965-05-28 1969-02-04 William J La Roche Inhalant dispenser
GB1182779A (en) * 1966-09-17 1970-03-04 Fisons Pharmaceuticals Ltd Inhalation Device
GB1268051A (en) 1968-06-07 1972-03-22 Fisons Pharmaceuticals Ltd Inhalation device
US3752027A (en) * 1970-02-09 1973-08-14 Gerber Garment Technology Inc Cutting tool for notching sheet material
GB1392945A (en) 1972-08-23 1975-05-07 Fisons Ltd Inhalation device
US3795244A (en) 1973-02-02 1974-03-05 Syntex Corp Inhalation device
FR2224175B1 (de) 1973-04-04 1978-04-14 Isf Spa
US4069819A (en) 1973-04-13 1978-01-24 Societa Farmaceutici S.P.A. Inhalation device
IT1017153B (it) 1974-07-15 1977-07-20 Isf Spa Apparecchio per inalazioni
YU41046B (en) 1974-08-22 1986-10-31 Schering Ag Medicine inholating device
GB1521000A (en) 1975-06-13 1978-08-09 Syntex Puerto Rico Inc Inhalation device
DE2528698C3 (de) 1975-06-27 1982-03-18 Bayer Ag, 5090 Leverkusen 7-Sulfonylacetylamino-substituierte Cumarinverbindungen und ein Verfahren zu deren Herstellung sowie die Verwendung dieser Verbindungen zur Herstellung von optischer Cumarin-Aufhellern
US4192309A (en) 1978-09-05 1980-03-11 Syntex Puerto Rico, Inc. Inhalation device with capsule opener
IT1116047B (it) * 1979-04-27 1986-02-10 Sigma Tau Ind Farmaceuti Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
ES8206980A1 (es) 1980-10-30 1982-09-01 Riker Laboratories Inc Un dispositivo para facilitar la inhalacion oral de medica- mentos en forma de polvo
GB8316640D0 (en) * 1983-06-18 1983-07-20 Gill S S Introducing drainage tubing scopes/instruments into cavities
DE3345722A1 (de) 1983-12-17 1985-06-27 Boehringer Ingelheim KG, 6507 Ingelheim Inhalator
EP0177657B1 (de) * 1984-10-08 1988-05-11 Geilinger AG System zur Deckung des Energiebedarfes eines Raumes
AT384552B (de) 1985-08-01 1987-12-10 Hurka Wilhelm Inhalationsgeraet zur dosierung und verteilung von festkoerpern in die atemluft
JPS63143081A (ja) 1986-12-05 1988-06-15 メクト株式会社 吸入器
US5267965A (en) * 1988-07-06 1993-12-07 Ethicon, Inc. Safety trocar
JPH02102965A (ja) 1988-10-06 1990-04-16 Aisin Aw Co Ltd 自動変速機における油圧制御装置
US5421482A (en) * 1989-02-03 1995-06-06 Senetics, Inc. Indicator device responsive to axial force
IT1228460B (it) 1989-02-23 1991-06-19 Phidea S R L Inalatore monouso con capsula pre-forata
US5239991A (en) 1989-06-21 1993-08-31 Fisons Plc Disposable powder medicament inhalation device with peel-off cover
FR2649323B1 (fr) 1989-07-04 1995-06-30 Valois Dispositif de projection et de pulverisation d'une dose d'un produit divisable
DE3927170A1 (de) 1989-08-17 1991-02-21 Boehringer Ingelheim Kg Inhalator
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
IL98441A (en) 1990-06-14 1995-12-31 Rhone Poulenc Rorer Ltd Powder inhaler
DE4027391A1 (de) 1990-08-30 1992-03-12 Boehringer Ingelheim Kg Treibgasfreies inhalationsgeraet
US5507281A (en) 1990-08-30 1996-04-16 Boehringer Ingelheim Kg Device for initiating a mechanical switching operation in synchronism with the breathing
SE9002895D0 (sv) 1990-09-12 1990-09-12 Astra Ab Inhalation devices for dispensing powders i
US5042472A (en) 1990-10-15 1991-08-27 Merck & Co., Inc. Powder inhaler device
GB9026025D0 (en) 1990-11-29 1991-01-16 Boehringer Ingelheim Kg Inhalation device
US5350393A (en) * 1992-01-06 1994-09-27 Inbae Yoon Safety trocar penetrating instrument
US5797391A (en) 1991-03-28 1998-08-25 Rhone-Poulenc Rorer Limited Inhaler
GB9106649D0 (en) 1991-03-28 1991-05-15 Rhone Poulenc Rorer Ltd Novel inhaler
FR2676929B1 (fr) 1991-05-30 1994-02-11 Aerosols Bouchage Ste Fse Inhalateur de poudres.
JP3230056B2 (ja) * 1991-07-02 2001-11-19 インヘイル・インコーポレーテッド 薬剤のエーロゾル化服用量を形成する装置
ES2089474T3 (es) 1991-08-16 1996-10-01 Sandoz Ltd Inhalador para la administracion de sustancias en polvo.
DE4211475A1 (de) * 1991-12-14 1993-06-17 Asta Medica Ag Pulverinhalator
EP0558879B1 (de) 1992-03-04 1997-05-14 Astra Aktiebolag Wegwerfinhalator
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
GB9216038D0 (en) * 1992-07-28 1992-09-09 Bespak Plc Dispensing apparatus for powdered medicaments
HU217917B (hu) 1992-10-19 2000-05-28 Dura Pharmaceuticals Inc. Inhalálókészülék száraz porok inhalálásához
WO1994014492A2 (en) 1992-12-18 1994-07-07 Schering Corporation Inhaler for powdered medications
US5314417A (en) * 1992-12-22 1994-05-24 Ethicon, Inc. Safety trocar
US5896855A (en) 1992-12-24 1999-04-27 Rhone-Poulenc Rorer Limited Multi dose inhaler apparatus
IL108780A (en) 1993-02-27 1999-06-20 Fisons Plc inhaler
DE69413528T2 (de) 1993-04-06 1999-05-06 Minnesota Mining And Mfg. Co., Saint Paul, Minn. Vorrichtung zum deagglomerieren für trockenpulverinhalatoren
US5349947A (en) 1993-07-15 1994-09-27 Newhouse Michael T Dry powder inhaler and process that explosively discharges a dose of powder and gas from a soft plastic pillow
DE69413989T2 (de) 1993-08-18 1999-04-08 Fisons Plc, Ipswich, Suffolk Inhalator mit atemstromregelung
US5524613A (en) * 1993-08-25 1996-06-11 Habley Medical Technology Corporation Controlled multi-pharmaceutical inhaler
PT101450B (pt) 1994-02-02 1999-11-30 Hovione Produtos Farmaceuticos Novo dispositivo para inalacao
FI942196A (fi) 1994-05-11 1995-11-12 Orion Yhtymae Oy Jauheinhalaattori
ES2302332T3 (es) 1994-09-21 2008-07-01 Nektar Therapeutics Aparato y metodos para dispersar medicamentos en polvo seco.
FR2725626A1 (fr) 1994-10-18 1996-04-19 Sofab Dispositif pour l'inhalation de produits en poudre
SE9404140D0 (sv) * 1994-11-29 1994-11-29 Astra Ab Dose indicating device
JP3308425B2 (ja) * 1995-03-10 2002-07-29 株式会社ユニシアジェックス 鼻腔用投薬器
GB9505425D0 (en) 1995-03-17 1995-05-03 Unilever Plc Assay devices
US5921237A (en) 1995-04-24 1999-07-13 Dura Pharmaceuticals, Inc. Dry powder inhaler
JP3320261B2 (ja) 1995-06-01 2002-09-03 株式会社ユニシアジェックス 吸入式投薬器
SE9502800D0 (sv) 1995-08-10 1995-08-10 Astra Ab Disposable inhaler
SE9502799D0 (sv) 1995-08-10 1995-08-10 Astra Ab Device in inhalers
JP3317827B2 (ja) 1995-10-09 2002-08-26 株式会社ユニシアジェックス 投薬器
JP2000503565A (ja) 1996-01-03 2000-03-28 グラクソ、グループ、リミテッド 吸入装置
NZ331361A (en) * 1996-02-21 2000-01-28 Schering Corp Powder inhaler including swirl means for changing the flow direction of the powder and chimney means for reversing the flow direction
US5699789A (en) 1996-03-11 1997-12-23 Hendricks; Mark R. Dry powder inhaler
ES2205210T3 (es) 1996-04-29 2004-05-01 Quadrant Technologies Ltd. Procedimientos de inhalacion de polvos secos.
DE69829139T2 (de) * 1997-01-30 2006-04-06 Hitachi, Ltd. Medikator vom ansaugtyp
SE9700421D0 (sv) 1997-02-07 1997-02-07 Astra Ab Single dose inhaler I
SE9700422D0 (sv) 1997-02-07 1997-02-07 Astra Ab Single dose inhaler II
DE19704849B4 (de) * 1997-02-08 2011-02-17 Ing. Erich Pfeiffer Gmbh Austragvorrichtung für Medien
SE9700940D0 (sv) 1997-03-14 1997-03-14 Astra Ab Powder inhaler IV
US6006747A (en) 1997-03-20 1999-12-28 Dura Pharmaceuticals, Inc. Dry powder inhaler
CA2212430A1 (en) * 1997-08-07 1999-02-07 George Volgyesi Inhalation device
US6237590B1 (en) 1997-09-18 2001-05-29 Delsys Pharmaceutical Corporation Dry powder delivery system apparatus
US6116238A (en) 1997-12-02 2000-09-12 Dura Pharmaceuticals, Inc. Dry powder inhaler
GB9810126D0 (de) 1998-05-13 1998-07-08 Glaxo Group Ltd
US6082358A (en) * 1998-05-05 2000-07-04 1263152 Ontario Inc. Indicating device for aerosol container
US6729330B2 (en) * 1998-05-05 2004-05-04 Trudell Medical International Indicating device for aerosol container
US6336453B1 (en) * 1999-04-30 2002-01-08 Trudell Medical International Indicating device for aerosol container
US6390291B1 (en) 1998-12-18 2002-05-21 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
US6119853A (en) 1998-12-18 2000-09-19 Glaxo Wellcome Inc. Method and package for storing a pressurized container containing a drug
US6615826B1 (en) * 1999-02-26 2003-09-09 3M Innovative Properties Company Slow spray metered dose inhaler
FI108518B (fi) 1999-04-23 2002-02-15 Orion Yhtymae Oyj Jauheinhalaattori yhdistelmälääkkeelle
DE60030862T2 (de) 1999-07-23 2007-09-06 Mannkind Corp., Valencia Trockenpulverinhalator
ES2200730T1 (es) * 2000-04-04 2004-03-16 Wenco Llc Dispositivo de corte multi-hoja.
US6948494B1 (en) * 2000-05-10 2005-09-27 Innovative Devices, Llc. Medicament container with same side airflow inlet and outlet and method of use
US6443152B1 (en) * 2001-01-12 2002-09-03 Becton Dickinson And Company Medicament respiratory delivery device
US6766799B2 (en) * 2001-04-16 2004-07-27 Advanced Inhalation Research, Inc. Inhalation device
US6685294B2 (en) * 2001-04-30 2004-02-03 Hewlett-Packard Development Company, L.P. Method for controlling media ejection
WO2003041777A1 (en) 2001-11-14 2003-05-22 Nektar Therapeutics Aerosolization device with improved endpiece connection
ITMI20020078A1 (it) * 2002-01-16 2003-07-16 Fabrizio Niccolai Dispositivo utilizzabile nel tratamento di affezzioni delle vie respiratorie
US7516741B2 (en) * 2002-12-06 2009-04-14 Novartis Ag Aerosolization apparatus with feedback mechanism
WO2004112702A2 (en) * 2003-06-13 2004-12-29 Advanced Inhalation Research, Inc. Low dose pharmaceutical powders for inhalation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3669113A (en) * 1966-03-07 1972-06-13 Fisons Ltd Inhalation device
US3888253A (en) * 1972-08-04 1975-06-10 Beecham Group Ltd Device for administration of medicines
EP0388621A1 (de) * 1989-02-23 1990-09-26 PHIDEA S.p.A. Zur vollständigen Entleerung der Kapsel geeigneter Inhalator

Also Published As

Publication number Publication date
US20040154618A1 (en) 2004-08-12
CA2444129C (en) 2008-01-08
NZ528682A (en) 2005-02-25
US7146978B2 (en) 2006-12-12
HK1061658A1 (en) 2004-09-30
CA2444129A1 (en) 2002-10-24
MXPA03009412A (es) 2005-03-07
US20040154619A1 (en) 2004-08-12
WO2002083220A8 (en) 2003-03-06
US20040011360A1 (en) 2004-01-22
DE60208891D1 (de) 2006-04-13
PL374794A1 (en) 2005-10-31
US20040216738A1 (en) 2004-11-04
DK1381416T3 (da) 2006-05-29
US20060283448A1 (en) 2006-12-21
US6732732B2 (en) 2004-05-11
PL204303B1 (pl) 2009-12-31
ATE316397T1 (de) 2006-02-15
ES2256467T3 (es) 2006-07-16
US7278425B2 (en) 2007-10-09
DE60208891T2 (de) 2006-10-05
IL158357A0 (en) 2004-05-12
US20030150453A1 (en) 2003-08-14
AU2002255808B2 (en) 2007-08-02
JP2004526523A (ja) 2004-09-02
EP1381416A2 (de) 2004-01-21
IL158357A (en) 2013-02-28
CY1108214T1 (el) 2014-02-12
WO2002083220A2 (en) 2002-10-24
US6766799B2 (en) 2004-07-27

Similar Documents

Publication Publication Date Title
EP1381416B1 (de) Inhalationsgerät
AU2002255808A1 (en) Inhalation device and method
US20200316324A1 (en) Low Dose Pharmaceutical Powders for Inhalation
US20170290999A1 (en) Powder Inhaler Devices
KR102416895B1 (ko) 캡슐을 천공하여 그로부터 분말형 의약을 방출하는 장치 및 방법
EP1485154B1 (de) Inhalationsgerät für pulverförmige substanzen
AU2006201285B8 (en) Puncturing means for use in an inhalation device

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20031113

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DELONG, MARK

Inventor name: STAPLETON, KEVIN

Inventor name: WOLFF, MARK

Inventor name: EDWARDS, DAVID

Inventor name: DUNBAR, CRAIG

Inventor name: PENACHIO, ERNEST, E.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WOLFF, MARK

Inventor name: EDWARDS, DAVID

Inventor name: DUNBAR, CRAIG

Inventor name: DELONG, MARK

Inventor name: PENACHIO, ERNEST, E.

Inventor name: STAPLETON, KEVIN

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1061658

Country of ref document: HK

17Q First examination report despatched

Effective date: 20040913

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 60208891

Country of ref document: DE

Date of ref document: 20060413

Kind code of ref document: P

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: KIRKER & CIE SA

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20060401189

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2256467

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1061658

Country of ref document: HK

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20061026

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CY

Payment date: 20100308

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110320

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60208891

Country of ref document: DE

Representative=s name: STAUDT IP LAW, DE

REG Reference to a national code

Ref country code: DE

Ref legal event code: R082

Ref document number: 60208891

Country of ref document: DE

Representative=s name: STAUDT IP LAW, DE

Ref country code: DE

Ref legal event code: R081

Ref document number: 60208891

Country of ref document: DE

Owner name: CIVITAS THERAPEUTICS, INC., CHELSEA, US

Free format text: FORMER OWNER: ADVANCED INHALATION RESEARCH, INC., CAMBRIDGE, MASS., US

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: ALKERMES, INC., US

Effective date: 20160121

REG Reference to a national code

Ref country code: PT

Ref legal event code: PC4A

Owner name: , US

Effective date: 20160122

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

Free format text: REGISTERED BETWEEN 20160211 AND 20160217

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 15

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

Owner name: CIVITAS THERAPEUTICS, INC., US

Effective date: 20160524

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 16

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20210225

Year of fee payment: 20

Ref country code: FI

Payment date: 20210309

Year of fee payment: 20

Ref country code: CH

Payment date: 20210317

Year of fee payment: 20

Ref country code: GR

Payment date: 20210226

Year of fee payment: 20

Ref country code: IT

Payment date: 20210226

Year of fee payment: 20

Ref country code: IE

Payment date: 20210310

Year of fee payment: 20

Ref country code: NL

Payment date: 20210312

Year of fee payment: 20

Ref country code: LU

Payment date: 20210310

Year of fee payment: 20

Ref country code: PT

Payment date: 20210319

Year of fee payment: 20

Ref country code: MC

Payment date: 20210226

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20210310

Year of fee payment: 20

Ref country code: DK

Payment date: 20210310

Year of fee payment: 20

Ref country code: DE

Payment date: 20210310

Year of fee payment: 20

Ref country code: BE

Payment date: 20210224

Year of fee payment: 20

Ref country code: AT

Payment date: 20210225

Year of fee payment: 20

Ref country code: SE

Payment date: 20210311

Year of fee payment: 20

Ref country code: TR

Payment date: 20210226

Year of fee payment: 20

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20210406

Year of fee payment: 20

REG Reference to a national code

Ref country code: DE

Ref legal event code: R071

Ref document number: 60208891

Country of ref document: DE

REG Reference to a national code

Ref country code: DK

Ref legal event code: EUP

Expiry date: 20220320

REG Reference to a national code

Ref country code: NL

Ref legal event code: MK

Effective date: 20220319

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: BE

Ref legal event code: MK

Effective date: 20220320

REG Reference to a national code

Ref country code: FI

Ref legal event code: MAE

Ref country code: GB

Ref legal event code: PE20

Expiry date: 20220319

REG Reference to a national code

Ref country code: IE

Ref legal event code: MK9A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220319

REG Reference to a national code

Ref country code: SE

Ref legal event code: EUG

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK07

Ref document number: 316397

Country of ref document: AT

Kind code of ref document: T

Effective date: 20220320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220329

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20220627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220320

Ref country code: ES

Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION

Effective date: 20220321

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230411